BR112021007060A2 - compostos contendo deutério - Google Patents

compostos contendo deutério Download PDF

Info

Publication number
BR112021007060A2
BR112021007060A2 BR112021007060-5A BR112021007060A BR112021007060A2 BR 112021007060 A2 BR112021007060 A2 BR 112021007060A2 BR 112021007060 A BR112021007060 A BR 112021007060A BR 112021007060 A2 BR112021007060 A2 BR 112021007060A2
Authority
BR
Brazil
Prior art keywords
melflufen
deuterium
mol
compound
iii
Prior art date
Application number
BR112021007060-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Fredrik Lehmann
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of BR112021007060A2 publication Critical patent/BR112021007060A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112021007060-5A 2018-10-18 2019-10-17 compostos contendo deutério BR112021007060A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1816998.7 2018-10-18
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GB1909695.7 2019-07-05
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds
PCT/EP2019/078250 WO2020079165A1 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Publications (1)

Publication Number Publication Date
BR112021007060A2 true BR112021007060A2 (pt) 2021-07-20

Family

ID=68290247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021007060-5A BR112021007060A2 (pt) 2018-10-18 2019-10-17 compostos contendo deutério

Country Status (19)

Country Link
US (2) US12152087B2 (https=)
EP (1) EP3866931B1 (https=)
JP (2) JP7603199B2 (https=)
KR (1) KR102848971B1 (https=)
CN (1) CN112930214B (https=)
AU (1) AU2019362389B2 (https=)
BR (1) BR112021007060A2 (https=)
CA (1) CA3116198A1 (https=)
DK (1) DK3866931T3 (https=)
ES (1) ES2942468T3 (https=)
FI (1) FI3866931T3 (https=)
HU (1) HUE061801T2 (https=)
IL (1) IL282231B2 (https=)
MA (1) MA53904A (https=)
MX (1) MX2021004474A (https=)
PL (1) PL3866931T3 (https=)
SG (1) SG11202103726RA (https=)
WO (1) WO2020079165A1 (https=)
ZA (1) ZA202102492B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
EP4347615B1 (en) * 2021-06-01 2025-05-21 Synthon B.V. Process for making melflufen or a salt thereof
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
WO2023281007A1 (en) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CA3024230C (en) * 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
WO2014065751A1 (en) * 2012-10-26 2014-05-01 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
EA202091397A1 (ru) 2013-01-31 2020-09-04 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
KR20150115807A (ko) * 2013-02-05 2015-10-14 임파 악치엔게젤샤프트 위치-특이적 비대칭 중수소 풍부 카테콜아민 유도체 및 상기 화합물을 포함하는 약제
EA201791466A1 (ru) 2013-12-03 2017-11-30 Оспекс Фармасьютикалз, Инк. Способы получения соединений бензохинолина
CN110229159B (zh) * 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Also Published As

Publication number Publication date
US20210388024A1 (en) 2021-12-16
ZA202102492B (en) 2024-04-24
JP2022512736A (ja) 2022-02-07
US20250115637A1 (en) 2025-04-10
JP2024150488A (ja) 2024-10-23
DK3866931T3 (da) 2023-04-24
IL282231A (en) 2021-05-31
KR20210078487A (ko) 2021-06-28
PL3866931T3 (pl) 2023-06-19
WO2020079165A1 (en) 2020-04-23
ES2942468T3 (es) 2023-06-01
AU2019362389B2 (en) 2024-12-12
KR102848971B1 (ko) 2025-08-21
IL282231B2 (en) 2025-07-01
EP3866931B1 (en) 2023-02-15
MA53904A (fr) 2021-08-25
CA3116198A1 (en) 2020-04-23
SG11202103726RA (en) 2021-05-28
FI3866931T3 (fi) 2023-05-10
HUE061801T2 (hu) 2023-08-28
CN112930214A (zh) 2021-06-08
CN112930214B (zh) 2025-05-16
EP3866931A1 (en) 2021-08-25
US12152087B2 (en) 2024-11-26
IL282231B1 (en) 2025-03-01
JP7603199B2 (ja) 2024-12-20
MX2021004474A (es) 2021-08-24
AU2019362389A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
BR112021007060A2 (pt) compostos contendo deutério
EP3686184A2 (en) Ionizable compounds and compositions and uses thereof
US12152048B2 (en) Nitroxoline prodrug and use thereof
US12558337B2 (en) Formulations comprising melflufen
JP2022545047A (ja) 3-ヒドロキシ-5-プレグナン-20-オン誘導体およびその使用
CN101268085B (zh) 用于硼中子俘获治疗的硼化合物
HK40048606B (en) Compounds containing deuterium
HK40048606A (en) Compounds containing deuterium
TW201922690A (zh) 環-amp反應元素結合蛋白的抑制劑
EA045396B1 (ru) Соединения, содержащие дейтерий
CN118005717A (zh) 一种用于制备谷氨酰胺拮抗剂的6-重氮-5-氧代-己酰胺衍生物
JP2025538979A (ja) 結晶性カルバゾール誘導体およびその製造方法
CN118406058A (zh) 一种替莫唑胺-阿魏酸的药物共晶体及其制备方法
TW202417007A (zh) 用於硼中子捕獲療法之小分子
EP3081556A1 (en) Amide compound and pharmaceutical comprising same
HK40047998A (en) Nitroxoline prodrug and use thereof
EA048956B1 (ru) Фармацевтическая композиция, содержащая мелфлуфен
CN111138282A (zh) 绿原酸l-精氨酸盐及其用途

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: ONCOPEPTIDES AB (SE)

B25A Requested transfer of rights approved

Owner name: ONCOPEPTIDES INNOVATION AB (SE)